Synthesis, Potency, and In Vivo Profiles of Quinoline Containing Histamine H3Receptor Inverse Agonists
- 6 October 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (22) , 5439-5448
Abstract
A new structural series of histamine H3 receptor antagonist was developed. The new compounds are based on a quinoline core, appended with a required basic aminoethyl moiety, and with potency- and property-modulating heterocyclic substituents. The analogs have nanomolar and subnanomolar potency for the rat and human H3R in various in vitro assays, including radioligand competition binding as well as functional tests of H3 receptor-mediated calcium mobilization and GTPγS binding. The compounds possessed favorable drug-like properties, such as good PK, CNS penetration, and moderate protein binding across species. Several compounds were found to be efficacious in animal behavioral models of cognition and attention. Further studies on the pharmaceutic properties of this series of quinolines discovered a potential problem with photochemical instability, an issue which contributed to the discontinuation of this series from further development.Keywords
This publication has 30 references indexed in Scilit:
- Histamine H3 Receptor Antagonists: Preclinical Promise for Treating Obesity and Cognitive DisordersMolecular Interventions, 2006
- Histamine and its receptorsBritish Journal of Pharmacology, 2006
- Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonistsNaunyn-Schmiedeberg's Archives of Pharmacology, 2003
- Coordination of Histamine H3 Receptor Antagonists with Human Adrenal Cytochrome P450 EnzymesPharmacology, 2002
- Pharmacological characterization of H3 receptor antagonists with imidazole, thioimidazole and thioimidazoline polar groups in the side chainInflammation Research, 2000
- Central histaminergic system and cognitionNeuroscience & Biobehavioral Reviews, 2000
- Synthesis of Potent Non-imidazole Histamine H3-Receptor AntagonistsArchiv der Pharmazie, 1998
- [3H]‐thioperamide as a radioligand for the histamine H3receptor in rat cerebral cortexBritish Journal of Pharmacology, 1996
- H3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450British Journal of Pharmacology, 1992
- Three loci related to the src oncogene and tyrosine-specific protein kinase activity in DrosophilaNature, 1983